Navigation Links
Osseon Signs International Distribution Agreement With MBA Incorporado

SANTA ROSA, Calif., Sept. 22 /PRNewswire/ -- Osseon Therapeutics, Inc., a Santa Rosa, California, manufacturer of spinal medical devices for the minimally invasive treatment of spinal compression fractures, today announced it has signed a five-year agreement with MBA Incorporado, SL to distribute Osseon's suite of products in the European and South American markets. MBA is a leading medical device marketing and distribution organization and specializes in the sale of products used for treatment of the spine. MBA is the largest private independent distributor of orthopaedic devices in Europe, generating more than $100 million in total sales in 2008.

Osseon's product line features the Osseoflex and Osseoperm. These products combine to form a unique new procedure termed Osseoplasty to treat painful acute fractures of the vertebrae seen increasingly in older individuals with osteoporosis and osteo-traumatic injuries.

Osseoflex is a steerable and curvable needle that can access the majority of the vertebral body from a single percutaneous access point. The Osseoperm system is customized for delivering optimal viscosity cement and precise cement placement through the Osseoflex needle. The Osseoplasty procedure provides rapid stabilization of vertebral fractures and significant pain relief in most patients within the same day.

MBA will distribute Osseon's devices to physicians and hospitals throughout the European Union, including the United Kingdom, Germany, Spain, Portugal, Italy, Greece, Austria, Switzerland, Scandinavia, France, Benelux, Turkey and Germany, as well as Latin America.

"Osseon is excited to partner with MBA, the leading distributor of biomedical spine treatment products in Europe and South America," said Dr. John Stalcup, CEO of Osseon Therapeutics. "MBA is known as the 'state-of-the-science' innovator in these markets for medical devices, always at the forefront of distribution and support of advanced medical technologies. Having MBA as our exclusive distributor will bring immediate and long-lasting relationships with the leading physicians and hospitals treating spinal compression fractures. We are, indeed, pleased to have MBA as our sole representative."

Paul Griffin, MBA's Chief Operating Officer and a member of their Board of Directors said, "MBA is honored that Osseon has chosen our Organization as its marketing and distribution partner for this unique technology for Europe and South America. We are delighted with this Agreement, which represents a huge opportunity for both our Organizations to facilitate the introduction of this exciting and new therapeutic option to specialists in many countries outside the U.S., who are treating an ever-increasing number of painful vertebral compression fractures in older patients." Paul Griffin added, "We feel confident that the combination of Osseon's impressive product portfolio together with MBA's experienced team and marketing know-how will allow us to develop and grow a very successful business together as innovators in this key market. Osseon has state-of-the-art technology and MBA has the resources to bring these remarkable devices quickly and successfully into all of the major and most competitive markets outside the U.S."

"MBA has an excellent and long-established international reputation for marketing and distributing medical devices for independent innovators and an unparalleled reputation for customer service. The Agreement today between MBA and Osseon represents a major step forward in the expansion of these services into the key markets of Europe and Latin America."

Osseon Therapeutics, Inc. was incubated at the University of Northern California's Science and Technology Innovation Center in Santa Rosa. Its first-generation products have received both FDA clearance and CE Mark for product distribution in the United States and European Union.

To learn more about Osseon, please visit our website:

SOURCE Osseon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Osseon Receives CE Mark
2. New device finds early signs of eye disease in preemies
3. GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing
4. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
5. Haemonetics Signs Comprehensive Agreement with Blood Centers of America
6. GENova Biotherapeutics signs collaboration agreement with Prime BioResearch
7. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
8. HemCon Medical Technologies, Inc. signs exclusive global agreement with Zimmer Dental Inc. to distribute oral surgery dressings
9. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
10. Online Sign Making from Just Got Faster, Easier, & Greener with its New Revolutionary System
11. Patient Safety Technologies Signs Contract with Partners HealthCare, to Implement the Safety-Sponge(TM) System at Brigham & Womens Hospital
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center ... and is the only hospital in the region providing what is known as ... transcatheter pacing patients were revealed recently at a medical conference and published in ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or ... anticipated results, once a deal is signed. This quick-read guidance suggests that ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... During the recent 2015 Transcatheter Cardiovascular ... CA , Medinol Ltd. continued to introduce ... a satellite symposium, "The BioNIR eDES: The Role ... a renowned physician panel discussed the key attributes ... Stent System and the Medinol eDES Coronary Stent ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
Breaking Medicine Technology: